Cara Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Great. Good afternoon, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the 2021 health care conference today with Cara Therapeutics. Just a quick note that instead of going across the hall for the breakout session this year, you can ask the question by using the blue Ask a Question button on your screen, that will send them to me through a portal, and I can ask management those questions after the presentation.
Without further ado, let me turn it over to Cara's CEO, Derek Chalmers.
Great. Good afternoon, Jess, and thank you very much for the invitation to be here today, if not in-person, at least virtually. So let me start by saying 2021 is going to be a highly significant year for us here at Cara on a number of fronts. We do expect FDA approval for our lead product candidate, which is KORSUVA Injection. It's a breakthrough drug for the treatment
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |